Speakers

Alice Stanton

Alice Stanton

Postdoctoral Fellow

Massachusetts Institute of Technology

Bruce Morimoto

Bruce Morimoto

Vice President, Drug Development

Principal Consultant

Deepak Sampath

Deepak Sampath

Senior Vice President, Head of Research

Ultragenyx Pharmaceuticals

Fay Touti

Fay Touti

Director, Oligonucleotide & Conjugation Chemistry

Apellis Pharmaceuticals

Gerard Platenburg

Gerard Platenburg

Chief Scientific Officer

ProQR

Hélène Tran

Hélène Tran

Director of Oligotherapeutics Program

Servier

Hideaki Tomita

Hideaki Tomita

Group Leader (Biology)

Luxna Biotech

Ioana Panait

Ioana Panait

Senior Researcher

Beacon Research Operations, Hanson Wade

Jimmy Weterings

Jimmy Weterings

Vice President, Head of Oligonucleotide Therapeutics

Bonito Biosciences

Julie Garlick

Julie Garlick

Principal Scientist

Genentech

Kathrin Meyer

Kathrin Meyer

Chief Scientific Officer & Head of R&D

Alcyone Therapeutics

Meena Meena

Meena –

Senior Vice President, Translational DMPK & Clinical Pharmacology

Stoke Therapeutics

Mano Manoharan

Muthiah (Mano) Manoharan

Senior Vice President, Innovation Chemistry & Alnylam Distinguished Scientist

Alnylam Pharmaceuticals

Naim Nazef

Naim Nazef

Vice President - Oligonucleotide Chemistry

Denali Therapeutics Inc.

Nicole Lykens

Nicole Lykens

Director of Neurobiology, Global Nucleic Acid Therapies (GNAT)

Novo Nordisk

Paul Nioi

Paul Nioi

Senior Vice President, Research

Alnylam Pharmaceuticals

Puneet Anand

Puneet Anand

Senior Principal Scientist

Regeneron

Ron Wange

Ron Wange

Associate Director of Pharmacology & Toxicology

USA FDA (formerly)

Scott V. Dindot

Scott V. Dindot

Executive Director of Molecular Genetics

Ultragenyx Pharmaceuticals

Stefano Zanotti

Stefano Zanotti

Vice President & Head of Neuromuscular Research

Dyne Therapeutics